Peptide therapy hype on TikTok: separating signal from noise

What did @morepepsmorereps actually say?

The creator announced that "LMF-retide, which is SS-31, was granted FDA approval for the treatment of Bart syndrome under the drug name Forzinity" as of September 19th, 2025. They framed this as "another FDA approved peptide" and a win for the broader peptide community. That framing deserves some unpacking, because the approval is real but the context matters a lot.

The drug in question is elamipretide, also known by the research designation SS-31. It is a mitochondria-targeting tetrapeptide developed by Stealth BioTherapeutics and later advanced under different corporate structures. The condition they named, though mispronounced as "Bart syndrome," is Barth syndrome, a rare X-linked genetic disorder affecting mitochondrial function, primarily in young males. The approval is a legitimate milestone, but calling it a win for general peptide optimization culture stretches the facts considerably.

Does the science back this up?

The underlying science on elamipretide in Barth syndrome is real and has been building for years. Whether it validates the broader peptide wellness space the creator is implying, that is a much harder sell.

Barth syndrome involves a mutation in the gene encoding tafazzin, which disrupts cardiolipin remodeling in the inner mitochondrial membrane. Elamipretide works by binding cardiolipin directly and stabilizing mitochondrial cristae structure. The TAZPOWER trial, a Phase 2 randomized controlled trial (Kleiner et al., 2021, JACC: Heart Failure), showed improvements in exercise tolerance and skeletal muscle function in Barth syndrome patients. A subsequent open-label extension supported durability of those effects. This is legitimate, peer-reviewed, mechanistically coherent science. The FDA approval tracks with that evidence base. What it does not do is validate the use of SS-31 or related peptides in healthy adults seeking performance enhancement or recovery, a leap the creator implies without stating directly.

What did they get wrong (or right)?

Credit where it is due: the core announcement appears accurate. An FDA approval for elamipretide under the name Forzinity for Barth syndrome is consistent with publicly anticipated regulatory timelines for this drug. The creator correctly identified the research name SS-31 and the indication. That is more precision than most peptide content on TikTok manages.

But there are real problems here. First, the condition name. "Bart syndrome" is not the correct name. Barth syndrome is named after Dr. Peter Barth, and mispronouncing or misspelling it in a video seen by over 100,000 people is a meaningful error when the patient community is small and advocacy groups have worked hard for recognition. Second, and more substantively, framing a rare pediatric mitochondrial disease approval as a win for "the community" conflates two entirely different use cases. Barth syndrome patients are not peptide biohackers. The approval of Forzinity tells us almost nothing about the safety or efficacy of SS-31 analogs or compounded peptides used off-label for athletic recovery. Those are separate questions with separate evidence standards.

What should you actually know?

FDA approval of Forzinity is a genuine advance for a disease that affects roughly 1 in 300,000 to 400,000 live births. It is not an endorsement of peptide therapy broadly, and it is not evidence that compounded or gray-market SS-31 products are safe or effective for general use.

Elamipretide as Forzinity is a pharmaceutical product that went through controlled clinical trials in a specific patient population with a defined genetic defect. Compounded peptides sold in the research chemical or wellness market are not the same product, are not manufactured to the same standards, and have not been tested in healthy adults at any dose. The FDA approval of a branded drug does not change the regulatory status of compounded versions. FormBlends or any regulated telehealth provider would need to follow applicable prescribing guidelines and cannot treat an FDA-approved indication approval as a green light for off-label compounded use. Anyone encountering SS-31 products outside a licensed prescriber relationship should understand that distinction clearly.